Increased number of shares and votes in Bactiguard

During May 2020, the number of class B shares in Bactiguard Holding AB (publ) ("Bactiguard") has increased by 241,512. As a result, the total number of shares in the company as of May 29, 2020 amounted to 29,543,885 and the total number of votes to 69,543,885.

The increase is a result of the new issue of shares by way of set-off that was approved by the Annual General Meeting on April 28, as part of the payment for Vigilenz, as earlier communicated.

The total number of shares in Bactiguard has increased by 241,512 class B shares and as of the last trading day in May (29 May 2020) amounts to a total of 33,543,885 shares, of which 4,000,000 from class A and 29,543,885 class B shares. Votes have increased by 241,512 and a total of 69,543,885.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication 2020-05-29, at 08.00.
 

For further information, please contact:
Cecilia Edström, CEO, phone: +46 8 440 58 80
 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com